Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Radnai, B; Antus, C; Racz, B; Engelmann, P; Priber, JK; Tucsek, Z; Veres, B; Turi, Z; Lorand, T; Sumegi, B; Gallyas, F.
Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.
Mol Cancer. 2012; 11(5): 34-34.
Doi: 10.1186/1476-4598-11-34
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Radnai Balazs
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: 2,4-Dimethoxyphenyl-E-4-arylidene-3-isochromanone (IK11) was previously described to induce apoptotic death of A431 tumor cells. In this report, we investigated the molecular action of IK11 in the HepG2 human hepatocellular carcinoma cell line to increase our knowledge of the role of poly (ADP-ribose) polymerase (PARP), protein kinase B/Akt and mitogen activated protein kinase (MAPK) activation in the survival and death of tumor cells and to highlight the possible role of PARP-inhibitors in co-treatments with different cytotoxic agents in cancer therapy. Results: We found that sublethal concentrations of IK11 prevented proliferation, migration and entry of the cells into their G2 phase. At higher concentrations, IK11 induced reactive oxygen species (ROS) production, mitochondrial membrane depolarization, activation of c-Jun N-terminal kinase 2 (JNK2), and substantial loss of HepG2 cells. ROS production appeared marginal in mediating the cytotoxicity of IK11 since N-acetyl cysteine was unable to prevent it. However, the PARP inhibitor PJ34, although not a ROS scavenger, strongly inhibited both IK11-induced ROS production and cell death. JNK2 activation seemed to be a major mediator of the effect of IK11 since inhibition of JNK resulted in a substantial cytoprotection while inhibitors of the other kinases failed to do so. Inhibition of Akt slightly diminished the effect of IK11, while the JNK and Akt inhibitor and ROS scavenger trans-resveratrol completely protected against it. Conclusions: These results indicate significant involvement of PARP, a marginal role of ROS and a pro-apoptotic role of Akt in this system, and raise attention to a novel mechanism that should be considered when cancer therapy is augmented with PARP-inhibition, namely the cytoprotection by inhibition of JNK2.
- Find related publications in this database (using NLM MeSH Indexing)
- Acetylcysteine - pharmacology
- Apoptosis - drug effects Apoptosis - genetics
- Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism
- Cell Cycle Checkpoints - drug effects
- Cell Line, Tumor -
- Cell Movement - drug effects
- Hep G2 Cells -
- Humans -
- Liver Neoplasms - genetics Liver Neoplasms - metabolism
- Membrane Potential, Mitochondrial - drug effects
- Mitochondria - drug effects Mitochondria - metabolism
- Mitogen-Activated Protein Kinase 9 - metabolism
- Necrosis -
- Phenanthrenes - pharmacology
- Poly(ADP-ribose) Polymerases - antagonists & inhibitors
- Proto-Oncogene Proteins c-akt - metabolism
- RNA Interference -
- Reactive Oxygen Species - metabolism
- Signal Transduction - drug effects
- Find related publications in this database (Keywords)
- Poly(ADP-ribose)-polymerase (PARP)
- Mitogen activated protein kinase (MAPK)
- c-Jun N-terminal kinase (JNK)
- Protein kinase B (PKB/Akt)
- Mitochondrial depolarization